111 related articles for article (PubMed ID: 16682319)
1. Early versus delayed enalapril in patients with left ventricular systolic dysfunction: impact on morbidity and mortality 15 years after the SOLVD trial.
Ahn SA; Jong P; Yusuf S; Bangdiwala SI; Pouleur HG; Rousseau MF
J Am Coll Cardiol; 2006 May; 47(9):1904-5. PubMed ID: 16682319
[No Abstract] [Full Text] [Related]
2. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.
Vermes E; Tardif JC; Bourassa MG; Racine N; Levesque S; White M; Guerra PG; Ducharme A
Circulation; 2003 Jun; 107(23):2926-31. PubMed ID: 12771010
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
Ishani A; Weinhandl E; Zhao Z; Gilbertson DT; Collins AJ; Yusuf S; Herzog CA
J Am Coll Cardiol; 2005 Feb; 45(3):391-9. PubMed ID: 15680718
[TBL] [Abstract][Full Text] [Related]
4. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction.
Alsheikh-Ali AA; Wang PJ; Rand W; Konstam MA; Homoud MK; Link MS; Estes NA; Salem DN; Al-Ahmad AM
Am Heart J; 2004 Jun; 147(6):1061-5. PubMed ID: 15199356
[TBL] [Abstract][Full Text] [Related]
5. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.
de Denus S; Tardif JC; White M; Bourassa MG; Racine N; Levesque S; Ducharme A
Am Heart J; 2006 Oct; 152(4):705-12. PubMed ID: 16996842
[TBL] [Abstract][Full Text] [Related]
6. The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited.
Parker AB; Yusuf S; Naylor CD
Am Heart J; 2002 Dec; 144(6):941-7. PubMed ID: 12486418
[TBL] [Abstract][Full Text] [Related]
7. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.
Jong P; Yusuf S; Rousseau MF; Ahn SA; Bangdiwala SI
Lancet; 2003 May; 361(9372):1843-8. PubMed ID: 12788569
[TBL] [Abstract][Full Text] [Related]
8. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
9. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
Böhm M; Pogue J; Kindermann I; Pöss J; Koon T; Yusuf S
Eur J Heart Fail; 2014 Mar; 16(3):325-33. PubMed ID: 24464788
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life.
Ramaciotti C; Heistein LC; Coursey M; Lemler MS; Eapen RS; Iannaccone ST; Scott WA
Am J Cardiol; 2006 Sep; 98(6):825-7. PubMed ID: 16950195
[TBL] [Abstract][Full Text] [Related]
11. Left ventricular function and response to enalapril in patients with Duchenne muscular dystrophy during the second decade of life.
Giglio V
Am J Cardiol; 2007 Jan; 99(1):147-8. PubMed ID: 17196482
[No Abstract] [Full Text] [Related]
12. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
13. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry.
Shindler DM; Kostis JB; Yusuf S; Quinones MA; Pitt B; Stewart D; Pinkett T; Ghali JK; Wilson AC
Am J Cardiol; 1996 May; 77(11):1017-20. PubMed ID: 8644628
[TBL] [Abstract][Full Text] [Related]
14. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
Cardinale D; Colombo A; Sandri MT; Lamantia G; Colombo N; Civelli M; Martinelli G; Veglia F; Fiorentini C; Cipolla CM
Circulation; 2006 Dec; 114(23):2474-81. PubMed ID: 17101852
[TBL] [Abstract][Full Text] [Related]
15. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).
Vermes E; Ducharme A; Bourassa MG; Lessard M; White M; Tardif JC;
Circulation; 2003 Mar; 107(9):1291-6. PubMed ID: 12628950
[TBL] [Abstract][Full Text] [Related]
16. Letter by Hammoud et al regarding article "Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition".
Hammoud R; Vaccari CS; Khan BV
Circulation; 2007 Jun; 115(24):e637; author reply e638. PubMed ID: 17576877
[No Abstract] [Full Text] [Related]
17. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
Phillips CO; Kashani A; Ko DK; Francis G; Krumholz HM
Arch Intern Med; 2007 Oct; 167(18):1930-6. PubMed ID: 17923591
[TBL] [Abstract][Full Text] [Related]
18. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction.
Kostis JB
Am J Hypertens; 1995 Sep; 8(9):909-14. PubMed ID: 8541006
[TBL] [Abstract][Full Text] [Related]
19. Management of asymptomatic left ventricular dysfunction.
Haas GJ
Cleve Clin J Med; 2001 Mar; 68(3):249-55. PubMed ID: 11263853
[TBL] [Abstract][Full Text] [Related]
20. Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction.
Gradman AH; Papademetriou V
Am Heart J; 2009 Jun; 157(6 Suppl):S17-23. PubMed ID: 19450720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
